Shots:

• Amgen reports the launch and commercialization of Amgevita- a biosimilar of adalimumab- available in Brazil
• The ANVISA’s approval is based on the clinical study demonstrating bio-similarity with the reference biological product- via in vitro analyzes- PK & clinical information in patients with moderate to severe psoriasis and RA
• Amgevita is a fully human IgG1 mAb targeting TNFα- a cytokine which mediates the inflammatory response and has received ANVISA’s approval for RA- PsO- CD- UC- axSpA- HS in Apr’2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Behance